Triazolam intranasal - Fabre Kramer

Drug Profile

Triazolam intranasal - Fabre Kramer

Alternative Names: Hypnostat; TGAR01H

Latest Information Update: 17 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Insomnia

Most Recent Events

  • 14 Aug 2014 Questcor Pharmaceuticals has been acquired by Mallinckrodt plc
  • 21 Jan 2009 Phase-II clinical trials in Insomnia in USA (Intranasal)
  • 13 Oct 2005 Discontinued - Phase-II for Insomnia in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top